Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Interest & Investment Income (2022 - 2025)

Axsome Therapeutics' Interest & Investment Income history spans 4 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 46.97% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$6.6 million, changed 0.18%, while the annual FY2025 figure was -$6.6 million, 0.18% changed from the prior year.
  • Interest & Investment Income for Q4 2025 was -$1.2 million at Axsome Therapeutics, down from -$1.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at -$702000.0 in Q4 2023 and bottomed at -$2.7 million in Q2 2023.
  • The 4-year median for Interest & Investment Income is -$1.6 million (2022), against an average of -$1.7 million.
  • The largest annual shift saw Interest & Investment Income soared 68.6% in 2023 before it crashed 214.81% in 2024.
  • A 4-year view of Interest & Investment Income shows it stood at -$1.3 million in 2022, then soared by 46.94% to -$702000.0 in 2023, then plummeted by 214.81% to -$2.2 million in 2024, then surged by 46.97% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Interest & Investment Income are -$1.2 million (Q4 2025), -$1.1 million (Q3 2025), and -$1.8 million (Q2 2025).